


## Disulfide bonds


### lysozyme

pdb code: 1AZF



### ribonuclease

pdb code: 1ALF



113

## Combinatorial Chemistry: molecular diversity

"Synthesis and Applications of Small Molecule Libraries."

Thompson, L. A.; Ellman, J. A. *Chem. Rev.* **1996**, *96*, 555-600.

"Design, Synthesis, and Evaluation of Small-Molecule Libraries."

Ellman, J. A. *Acc. Chem. Res.* 1996, *29*, 132 -143.

Combinatorial Chemistry, Nicholas K. Terrett, Oxford University Press, London, 1998

pharmaceutical industry- drug discovery



Lead identification: literature (open & patent)  
nature (natural products)

Careful optimization of a lead structure via chemical synthesis  
"methyl-ethyl-butyl-futile game"

Number of marketable drugs per compounds that undergo preliminary biological testing  $\frac{1}{10,000}$  ← Rational drug design  
← Combinatorial chemistry

114

Peptides: poor bioavailability, poor transport, easily metabolized:  
poor drug candidates.

However, they are the natural substrates for many enzymes  
and receptors (drug targets) and have well-defined  
conformations: excellent lead compounds

Enzymes: converts a substrate to a distinct product

Receptor: binds a ligand (no reaction), causing a chain of physio-  
chemical events leading to a pharmacological response.

Agonist: substance that interacts (binds) with a receptor and elicits  
an observable response

Antagonist: substances inhibits the affect of an agonist, but has no  
biological activity of its own

115

Example of molecular diversity:

tetra-peptide:  $\text{H}_2\text{N-A-B-C-D-CO}_2\text{H}$

consider only the 20 natural amino acids (L-series)

$20^4 = 160,000$  different tetra-peptides !

now include the 19 D-amino acids (20 L + 19 D = 39)

$39^4 = 2.3$  million different tetra-peptides !!

now include 20 unnatural amino acids


$59^4 = 12$  million different tetra-peptides !!!!

Combinatorial chemistry: method by which a family (library) of related  
compounds (structurally & synthetically) can be prepared and  
evaluated (screened)

For multi-step synthesis, one must use solid-phase synthetic approach  
in order to expedite purification of intermediates


116

### Split synthesis (mixture libraries)




117

### Split synthesis (con' t)



118

Why not?




Reactivity of the coupling reaction may be different and this could bias the library


Split synthesis approach, all compounds are equally represented (each coupling is individually controlled)

119

Deconvolution of the library  
via biological activity and sub-library re-synthesis



120




#### Problems:

- deconvolution of the library can be labor intensive
- can be fooled by low concentrations of highly active compounds
- activity is dependent upon the compound and its concentration
- activity observed is the the combined activity of the entire library

#### Advantage:


- can synthesize a very large number of compounds very quickly and relatively easily depending on the chemistry.

## Encoded Libraries




123

## Encoded libraries (con' t)





124


## Synthesis of an encoded library



125




## Reading the code




126

## “On-Bead” Assay for Receptor Binding using a Fluorescently Labeled Receptor



127


## Spatially Addressable, Parallel Synthesis



128



### Spatially Addressable, Parallel Synthesis (con' t)



129

### Spatially addressable, parallel libraries

Advantage:

- synthesizing pure compounds, no need to deconvolute the library

Disadvantage

- libraries tend to be much smaller

130

## Diversomer apparatus




Figure 1. Schematic representation of an eight-PIN synthesizer. The apparatus consists of an array of gas dispersion tubes (PINS), a reservoir block with multiple reaction wells, a holder block, a manifold, and gaskets. Clamps are not depicted.




Figure 2. A now dated photograph of the 40-array apparatus interfaced to the x,y,z robot used for liquid delivery (September 1993).

*Acc. Chem. Res.* **1996**, *29*, 114-122


131

## ACE Inhibitors





aspartyl  
protease

renin




Zn<sup>2+</sup>  
protease

angiotensin converting  
enzyme (ACE)



132

**Proteases:** catalyzes the hydrolysis of peptide bonds





1. Serine protease
2. Cysteine protease
3. Aspartyl protease
4. Zinc (metallo) protease


**ACE:** zinc protease ( no x-ray or NMR structure),  
 compared to carboxypeptidase or thermolysin  
 important catalytic groups: Glu-270, His-196, His-69  
 (catalytic triad)

133

### ACE inhibitor Library




**240 cmpds, each are multiple stereoisomers**




134

## Parallel Synthesis of a Benzodiazepine Library




## Parallel Synthesis of a Benzodiazepine Library


### 2-aminobenzophenones



### α-amino acids



### alkylating agents



2 (2-aminobenzophenone) x 12 (amino acids) x 8 (alkyl halides) = 192 compounds


| R <sup>3</sup> | Amino Acid (R <sup>2</sup> ) |   |   |   |     |   |   |   |   |   |   |   |
|----------------|------------------------------|---|---|---|-----|---|---|---|---|---|---|---|
|                | V                            | A | D | W | Nle | G | L | K | I | A | F | W |
| H              | •                            | • | • | • | •   | • | • | • | • | • | • | • |
| Me             | •                            | • | • | • | •   | • | • | • | • | • | • | • |
| Bn             | •                            | • | • | • | •   | • | • | • | • | • | • | • |
| Acetamide      | •                            | • | • | • | •   | • | • | • | • | • | • | • |
| Et             | •                            | • | • | • | •   | • | • | • | • | • | • | • |
| n-Pr           | •                            | • | • | • | •   | • | • | • | • | • | • | • |
| Isopyl         | •                            | • | • | • | •   | • | • | • | • | • | • | • |
| Xylyl          | •                            | • | • | • | •   | • | • | • | • | • | • | • |

FIG. 3. Receptor binding affinity of 1,4-benzodiazepine derivatives. Receptor binding affinity of the 1,4-benzodiazepine derivatives at 7.5  $\mu$ M is monitored by the percent displacement of <sup>125</sup>I-labeled CCK-8 from the CCK A receptors as observed by the relative signal intensity upon PhosphorImager exposure. Group R<sup>2</sup> corresponds to the side chain of the amino acid that is incorporated into the benzodiazepine structure. The absolute configurations for most compounds is S, except for the derivatives in the last three columns (incorporating amino acids A, F, and W), where the absolute configuration is R. Nle, norleucine; Bn, benzyl; n-Pr, n-propyl. In the receptor binding assay, the two benzodiazepine derivatives prepared from valine with R<sup>2</sup> = H were replaced with compound 9 (Table 1).

Cholecystikinin (CCK)  
CCK-8: Asp-Tyr(SO<sub>3</sub>H)-Met-Gly-Trp-Met-Asp-Phe-NH<sub>2</sub>


136

## $\beta$ -Turn Mimics:



137

## Combinatorial synthesis of linchpin $\beta$ -turn mimic



Evaluated for Somatostatin receptor binding

$n = 1, 2 \times R_2 = 34 \text{ AA} \times R_3 = 10 = 1292 \beta\text{-turn mimics}$

138